P2-137 - Association of body mass index and gastrointestinal chemotherapy toxicity in breast cancer patients: A preliminary study.

Survival of breast cancer patients who are obese is worse than normal weight or underweight. Gastrointestinal (GI) chemotherapy toxicity is increase in patient with low skeletal mass. Sarcopenia obesity is emerging problem in elderly population, but there is limited data in breast cancer patient. The aim of this study is to evaluate association between Body Mass Index (BMI) and GI chemotherapy toxicity in breast cancer patients. A cross-sectional study was done in our general hospital starting from October 2018 until February 2019. The patients included in this study are those diagnosed with breast cancer and have undergone chemotherapy. Chemotherapy toxicity is assessed using the National Cancer Institute Common Toxicity Criteria (NCI CTC) with a cut off above 1 point and BMI is categorised using WHO Asia pacific criteria measured with cut off less than 18.5 as underweight, 18.5-22.9 as normal range, 23-24.9 as at risk and 25-29.9 as Obese 1. The association between BMI and GI chemotherapy toxicity was analysed with Chi-square using SPSS version 24. The data collected from 31 patients with mean age of 47.74±9.245. Mean BMI is 23.9±4.11 with underweight 6.3%, normal 46.9% and overweight 9.4%, pre-obese 34.4%, obese type-1 3.1%. NCI CTC Constipation toxicity score 0 (71%), 1 (22.6%), 2 (6.5%). NCI CTC Diarrhoea score 0 (80.6%), 1 (12.9%), 2 (6.5%). 29 patients were reported with no GI toxicity and 2 patients were reported with GI toxicity. No toxicity was reported in 16 patients with normal BMI and 2 toxicity were reported in 15 obese patients (p-value=0.226). The association between obesity and GI chemotherapy toxicity is not clinically significant but further study with a larger sample size is needed to confirm this findings. [ABSTRACT FROM AUTHOR]